CYCLERION THERAPEUTICS INC (CYCN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.25-14.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CYCN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -52.7% |
| Our one-year growth estimate | diamond | -61.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 8.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
CYCN — M&A activity — Changes in Control of Registrant
Dated 2026-04-01
Changes in Control of Registrant. To the extent required by this Item, the information included in
Why it matters: Revenue growth trends will show if CYCLERION can improve its financial health.
Worry ifQ2 revenue growth reported below the median growth rate for the sector.
Less concerning ifQ2 revenue growth exceeds the median growth rate for the sector.
Why it matters: Partnerships can help develop CYC-126 and increase its market potential.
Supportive ifA press release announcing a new partnership for CYC-126 development.
Worry ifThere are no new partnerships. CYC-126 development is delayed.
Why it matters: Finishing this deal could help CYCLERION grow and improve its market position.
Supportive ifA public announcement that the deal is done.
Worry ifFurther delays or setbacks in the acquisition process.
Why it matters: Starting this study is important for the drug's development and Cyclerion's future. It shows they are advancing their product pipeline.
Supportive ifThe Phase 2 Proof-of-Concept study for CYC-126 starts in the second half of 2026.
Worry ifThe study is delayed or not initiated as planned.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$136 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $1,091 loss on $10,000 · 10.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,677 loss on $10,000 · 66.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Cyclerion needs to cut losses to stay financially healthy. This shows they manage costs well.
Worry ifOperating losses will drop to less than negative $1.8M next quarter.
Less concerning ifOperating losses will stay the same or get worse than negative $1.8M.
Why it matters: A drop in revenue growth could signal a slowdown in the healthcare sector, affecting CYCLERION.
Worry ifHealthcare sector revenue growth is below its usual rate.
Less concerning ifHealthcare sector revenue growth stays above its usual rate.
Why it matters: Completing this acquisition is key for Cyclerion's growth strategy. It could enhance their market position.
Supportive ifThe acquisition is done. Contingent value rights go to shareholders.
Worry ifThe acquisition faces delays or fails to close as planned.